secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001384101-22-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q4 2021 revenue $67.3M (+95% YoY); guides 2022 revenue $260-275M
-------------------------------------------------------------------------

- Q4 2021 revenue $67.3M (+95% YoY); full-year 2021 revenue $219.5M (+87% YoY).
- Net loss $10.5M in Q4 ($0.15 per share); full-year loss $75.6M ($1.11 per share).
- Test volume grew to 22,300 in Q4 (+70% YoY); full-year volume 78,565 (+77% YoY).
- 2022 revenue guidance $260M-$275M, representing 18-25% YoY growth.
- Completed acquisitions of Decipher Biosciences and HalioDx; launched Decipher Bladder test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410122000026/0001384101-22-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410122000026/vcyt-20220228.htm
  HTML page:      https://secwatch.observer/filing/0001384101-22-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer